Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Closed Initial Public Offering on July 2, 2018Completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients Mr. Gerald Lieberman was Appointed as Chairman of the Board of Directors ...
-
JERUSALEM, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW), announced today the appointment of Mr. Gerald Lieberman as the chairman of the board of directors, effective as...
-
A second and final part of the study will evaluate selected dose regimens chosen based on part 1 JERUSALEM, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it...
-
JERUSALEM, July 02, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (NASDAQ:ENTXW), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally...
-
JERUSALEM, June 28, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (NASDAQ:ENTXW), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally...